Douglas Guedes de Castro1, Juliana Matiello2, Wilson Roa3, Sunita Ghosh3, Lucyna Kepka4, Narendra Kumar5, Valery Sinaika6, Darejan Lomidze7, Dalenda Hentati8, Eduardo Rosenblatt9, Elena Fidarova9. 1. AC Camargo Cancer Center, São Paulo, Brazil. Electronic address: dougguedes@uol.com.br. 2. Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil. 3. University of Alberta, Alberta Health Services-Cancer Control, Edmonton, Alberta, Canada. 4. Military Institute of Medicine, Warsaw, Poland. 5. Postgraduate Institute of Medical Education and Research, Chandigarh, India. 6. N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus. 7. High Technology Medical Center, Tbilisi, Georgia. 8. Institut National de Cancer Salah Azaiz, Tunis, Tunisia. 9. International Atomic Energy Agency, Vienna, Austria.
Abstract
PURPOSE: To perform a subset analysis of survival outcomes in elderly patients with glioblastoma from a randomized phase 3 trial comparing 2 short-course radiation therapy (RT) regimens in elderly and/or frail patients. METHODS AND MATERIALS: The original trial population included elderly and/or frail patients with a diagnosis of glioblastoma. Patients joined the phase 3, randomized, multicenter, prospective, noninferiority trial; were assigned to 1 of 2 groups in a 1:1 ratio, either short-course RT (25 Gy in 5 fractions, arm 1) or commonly used RT (40 Gy in 15 fractions, arm 2); and were stratified by age (<65 years and ≥65 years), Karnofsky Performance Status (KPS), and extent of surgery. For the subset analysis in this study, only patients aged ≥65 years were evaluated (elderly and frail patients were defined as patients aged ≥65 years with KPS of 50%-70%; elderly and non-frail patients were defined as patients aged ≥65 years with KPS of 80%-100%); 61 of the 98 initial patients comprised the patient population, with 26 patients randomized to arm 1 and 35 to arm 2. RESULTS: In this unplanned analysis, the short-course RT results were not statistically significantly different from the results of commonly used RT in elderly patients. The median overall survival time was 6.8 months (95% confidence interval [CI], 4.5-9.1 months) in arm 1 and 6.2 months (95% CI, 4.7-7.7 months) in arm 2 (P=.936). The median progression-free survival time was 4.3 months (95% CI, 2.6-5.9 months) in arm 1 and 3.2 months (95% CI, 0.1-6.3 months) in arm 2 (P=.706). CONCLUSIONS: A short-course RT regimen of 25 Gy in 5 fractions is an acceptable treatment option for patients aged ≥65 years, mainly those with a poor performance status or contraindication to chemotherapy, which would be indicated in cases of methylated O6 methylguanine-DNA-methyltransferase promoter tumors.
RCT Entities:
PURPOSE: To perform a subset analysis of survival outcomes in elderly patients with glioblastoma from a randomized phase 3 trial comparing 2 short-course radiation therapy (RT) regimens in elderly and/or frail patients. METHODS AND MATERIALS: The original trial population included elderly and/or frail patients with a diagnosis of glioblastoma. Patients joined the phase 3, randomized, multicenter, prospective, noninferiority trial; were assigned to 1 of 2 groups in a 1:1 ratio, either short-course RT (25 Gy in 5 fractions, arm 1) or commonly used RT (40 Gy in 15 fractions, arm 2); and were stratified by age (<65 years and ≥65 years), Karnofsky Performance Status (KPS), and extent of surgery. For the subset analysis in this study, only patients aged ≥65 years were evaluated (elderly and frail patients were defined as patients aged ≥65 years with KPS of 50%-70%; elderly and non-frail patients were defined as patients aged ≥65 years with KPS of 80%-100%); 61 of the 98 initial patients comprised the patient population, with 26 patients randomized to arm 1 and 35 to arm 2. RESULTS: In this unplanned analysis, the short-course RT results were not statistically significantly different from the results of commonly used RT in elderly patients. The median overall survival time was 6.8 months (95% confidence interval [CI], 4.5-9.1 months) in arm 1 and 6.2 months (95% CI, 4.7-7.7 months) in arm 2 (P=.936). The median progression-free survival time was 4.3 months (95% CI, 2.6-5.9 months) in arm 1 and 3.2 months (95% CI, 0.1-6.3 months) in arm 2 (P=.706). CONCLUSIONS: A short-course RT regimen of 25 Gy in 5 fractions is an acceptable treatment option for patients aged ≥65 years, mainly those with a poor performance status or contraindication to chemotherapy, which would be indicated in cases of methylated O6 methylguanine-DNA-methyltransferase promoter tumors.
Authors: Emily V Dressler; Meng Liu; Catherine R Garcia; Therese A Dolecek; Thomas Pittman; Bin Huang; John L Villano Journal: Neurooncol Pract Date: 2018-05-22
Authors: Michael Karsy; Nam Yoon; Lillian Boettcher; Randy Jensen; Lubdha Shah; Joel MacDonald; Sarah T Menacho Journal: J Neurooncol Date: 2018-02-01 Impact factor: 4.130
Authors: Brandon A Sherrod; Nicholas T Gamboa; Christopher Wilkerson; Herschel Wilde; Mohammed A Azab; Michael Karsy; Randy L Jensen; Sarah T Menacho Journal: J Neurooncol Date: 2019-05-04 Impact factor: 4.130
Authors: Joshua D Palmer; Deepak Bhamidipati; Minesh Mehta; Noelle L Williams; Adam P Dicker; Maria Werner-Wasik; Wenyin Shi Journal: J Neurooncol Date: 2018-08-07 Impact factor: 4.130
Authors: Carmen Balaña; Jaume Capellades; Estela Pineda; Anna Estival; Josep Puig; Sira Domenech; Eugenia Verger; Teresa Pujol; Maria Martinez-García; Laura Oleaga; JoseMaria Velarde; Carlos Mesia; Rafael Fuentes; Jordi Marruecos; Sonia Del Barco; Salvador Villà; Cristina Carrato; Oscar Gallego; Miguel Gil-Gil; Jordi Craven-Bartle; Francesc Alameda Journal: Cancer Med Date: 2017-11-03 Impact factor: 4.452
Authors: J Biau; E Chautard; E De Schlichting; G Dupic; B Pereira; A Fogli; M Müller-Barthélémy; P Dalloz; T Khalil; A F Dillies; X Durando; C Godfraind; P Verrelle Journal: Radiat Oncol Date: 2017-12-06 Impact factor: 3.481